Literature DB >> 6414522

The subcellular location of isozymes of NADP-isocitrate dehydrogenase in tissues from pig, ox and rat.

G W Plaut, M Cook, T Aogaichi.   

Abstract

Antibodies against purified NADP-isocitrate dehydrogenase from pig liver cytosol and pig heart were raised in rabbits. The purified enzymes from these sources are different proteins, as demonstrated by differences in electrophoretic mobility and absence of crossreactivity by immunotitration and immunodiffusion. The NADP-isocitrate dehydrogenase in the soluble supernatant homogenate fraction from pig liver, kidney cortex, brain and erythrocyte hemolyzate was identical with the purified enzyme from pig liver cytosol, as determined by electrophoretic mobility and immunological techniques. The enzyme in extracts of mitochondria from pig heart, kidney, liver and brain was identical with the purified pig heart enzyme by the same criteria. However, the 'mitochondrial' isozyme was the major component also in the soluble supernatant fraction of pig heart homogenate. The 'cytosolic' isozyme accounted for only 1-2% of total NADP-isocitrate dehydrogenase in pig heart, as determined by separation of the isozymes with agarose gel electrophoresis and immunotitration. The mitochondrial isozyme was also the predominant NADP-isocitrate dehydrogenase in porcine skeletal muscle. The ratio of cytosolic/mitochondrial isozyme for porcine whole tissue extract, determined by immunotitration, was about 2 for liver and 1 for kidney cortex and brain. The distribution of isozymes in cell homogenate fractions from ox and rat tissues corresponded to that observed in organs of porcine origin. The mitochondrial and cytosolic isozymes from ox and rat tissues exhibited crossreactivity with the antibodies against the pig heart and pig liver cytosol enzyme, respectively, and the electrophoretic migration patterns were similar qualitatively to those found for the isozymes in porcine tissues. Nevertheless, there were species specific differences in the characteristics of each of the corresponding isozymes. NAD-isocitrate dehydrogenase was not inhibited by the antibodies, confirming that the protein is distinct from that of either isozyme of NADP-isocitrate dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414522     DOI: 10.1016/0304-4165(83)90177-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Microphotometric determination of enzymes in brain sections. IV. Isocitrate dehydrogenases.

Authors:  P Kugler; S Vogel
Journal:  Histochemistry       Date:  1991

Review 2.  The power to reduce: pyridine nucleotides--small molecules with a multitude of functions.

Authors:  Nadine Pollak; Christian Dölle; Mathias Ziegler
Journal:  Biochem J       Date:  2007-03-01       Impact factor: 3.857

3.  Calcium-dependent activation of mitochondrial metabolism in mammalian cells.

Authors:  Lawrence D Gaspers; Andrew P Thomas
Journal:  Methods       Date:  2008-10-12       Impact factor: 3.608

Review 4.  In situ measurements of enzyme activities in the brain.

Authors:  P Kugler
Journal:  Histochem J       Date:  1993-05

5.  Comparative Approach of the de novo Fatty Acid Synthesis (Lipogenesis) between Ruminant and Non Ruminant Mammalian Species: From Biochemical Level to the Main Regulatory Lipogenic Genes.

Authors:  G P Laliotis; I Bizelis; E Rogdakis
Journal:  Curr Genomics       Date:  2010-05       Impact factor: 2.236

6.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

7.  Cloning of a cDNA encoding bovine mitochondrial NADP(+)-specific isocitrate dehydrogenase and structural comparison with its isoenzymes from different species.

Authors:  T L Huh; J H Ryu; J W Huh; H C Sung; I U Oh; B J Song; R L Veech
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

8.  Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.

Authors:  Farhad Ravandi; Keyur Patel; Rajyalakshmi Luthra; Stefan Faderl; Marina Konopleva; Tapan Kadia; Mark Brandt; Sherry Pierce; Steven Kornblau; Michael Andreeff; Xuemei Wang; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.921

9.  The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.

Authors:  Dinesh Rakheja; L Jeffrey Medeiros; Scott Bevan; Weina Chen
Journal:  Front Oncol       Date:  2013-07-02       Impact factor: 6.244

10.  MNADK, a novel liver-enriched mitochondrion-localized NAD kinase.

Authors:  Ren Zhang
Journal:  Biol Open       Date:  2013-03-05       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.